Replimune Group, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, April 13, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Replimune Group, Inc. (NASDAQ: REPL). The investigation focuses on Replimune’s executive officers and whether investor losses may be recovered under federal securities laws.

What if I purchased Replimune securities?
If you purchased Replimune securities and suffered losses on your investment, join our investigation now: Click here to join the investigation.
Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471.
There is no cost or obligation to you.

Background of the investigation
On April 10, 2026, Replimune Group, Inc. disclosed that the U.S. Food and Drug Administration had issued a Complete Response Letter regarding the Company’s resubmitted Biologics License Application for RP1 (vusolimogene oderparepvec). The FDA determined that the data presented were insufficient to establish substantial evidence of effectiveness and further stated that the additional analyses submitted by the Company did not alter its prior conclusion that the IGNYTE trial was not an adequate and well-controlled clinical investigation capable of providing such evidence.

The Company had previously received a Complete Response Letter in July 2025 identifying deficiencies in the clinical evidence supporting the application. Following that rejection, Replimune represented that it had addressed the FDA’s concerns through additional analyses and regulatory engagement and advanced the application toward an April 10, 2026 PDUFA date.

However, the April 10, 2026 Complete Response Letter revealed that these efforts did not resolve the deficiencies previously identified by the FDA.

Following these disclosures, Replimune’s stock price declined significantly, damaging investors.

In liht of this disclosure, Johnson Fistel is investigating whether Replimune complied with the federal securities laws. If you suffered losses from your investment in Replimune stock, contact Johnson Fistel.

About Johnson Fistel, PLLP | Securities Fraud & Investor Rights
Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit www.johnsonfistel.com.

Achievements
In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, reflecting the firm’s effectiveness in advocating for investors and recovering approximately $90,725,000 for clients in cases where it served as lead or co-lead counsel.

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.

Contact
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101
James Baker, Investor Relations – or – Frank J. Johnson, Esq.
(619) 814-4471 | jimb@johnsonfistel.com | fjohnson@johnsonfistel.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.